Ekaterina Neborak

Dr. Ekaterina Neborak


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2022 in Molecules
Verified
Journal Article
Open access
PDF file
ENEkaterina Neborak
Ekaterina Neborak
Altynay KaldybayevaAltynay Kaldybayeva
Altynay Kaldybayeva
LBLylia Bey
Lylia Bey
AMAigul Erbosynovna Malmakova
Aigul Erbosynovna Malmakova
ATAnna S. Tveritinova
Anna S. Tveritinova
DZDmitry D. Zhdanov
Dmitry D. Zhdanov
Polyamine (PA) catabolism is often reduced in cancer cells. The activation of this metabolic pathway produces cytotoxic substances that might cause apoptosis in cancer cells. Chemical compounds able to restore the level of PA catabolism in tumors could become potential antineoplastic agents. The search for activators of PA catabolism among bicyclononan-9-ones is a promising strategy for drug development. The aim of the study was to evaluate the biological activity of new 3,7-diazabicyclo[3.3.1]nonan-9-one derivatives that have antiproliferative properties by accelerating PA catabolism. Eight bispidine derivatives were synthetized and demonstrated the ability to activate PA catabolism in regenerating rat liver homogenates. However, only three of them demonstrated a potent ability to decrease the viability of cancer cells in the MTT assay. Compounds 4c and 4e could induce apoptosis more effectively in cancer HepG2 cells rather than in normal WI-38 fibroblasts. The lead compound 4e could significantly enhance cancer cell death, but not the death of normal cells if PAs were added to the cell culture media. Thus, the bispidine derivative 4e 3-(3-methoxypropyl)-7-[3-(1H-piperazin-1-yl)ethyl]-3,7-diazabicyclo[3.3.1]nonane could become a potential anticancer drug substance whose mechanism relies on the induction of PA catabolism in cancer cells.

27 June 2025 in Anticancer Research
Verified
Journal Article
Closed access
ISIrina P. Smirnova
Irina P. Smirnova
ENEkaterina Neborak
Ekaterina Neborak
VLVictor F. Larichev
Victor F. Larichev
LGLyudmila A. Gavrilyuk
Lyudmila A. Gavrilyuk
DZDmitry D. Zhdanov
Dmitry D. Zhdanov
Enzymatic anticancer therapies are actively investigated as they can selectively deprive cancer cells of essential nutrients. L-lysine-α-oxidases of different origins have been reported as potential anticancer enzymes with a significant antitumor potency. This study aimed to evaluate the cytotoxic and antitumor activity of L-lysine-α-oxidase obtained from the domestic strain of Trichoderma harzianum Rifai VKPM F-180. The melanoma cell line A875 and normal keratinocytes HaCaT were used for cytotoxicity testing. Murine solid tumors sarcoma 45, carcinosarcoma W-256, carcinoma PC-1 and hepatoma 22 were used for experiments with animals. Tumor growth inhibition (TGI) was the primary measure of antitumor efficacy. L-lysine-α-oxidase exhibited selective cytotoxicity toward melanoma cells (IC50=0.09 μg/ml) compared to HaCaT cells (IC50=0.38 μg/ml). In animal models, the enzyme significantly inhibited growth of sarcoma 45, carcinoma PC-1, and hepatoma 22, with TGI ranging from 25% to 41% at 35 U/kg by the 8th or 9th day post-treatment. However, carcinosarcoma W-256, a reactive oxygen species-producing tumor, demonstrated lower sensitivity, particularly at higher enzyme doses. L-lysine-α-oxidase from Trichoderma harzianum Rifai demonstrates promising selective cytotoxicity and antitumor activity, especially in ROS-sensitive tumors.